DRG Market Assessment reports

Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug…

Roche / Chugai’s Hemlibra has fundamentally transformed the treatment of hemophilia A. For patients with inhibitors who were previously reliant on bypass agent prophylaxis, Hemlibra provides…

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

Roche / Chugai’s Hemlibra has fundamentally transformed the treatment of hemophilia A. For patients with inhibitors who were previously reliant on bypass agent prophylaxis, Hemlibra provides…

The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…

Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…

Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…

Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…

Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…

The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…

The breast cancer therapy market is one of the most dynamic markets in the oncology space in mainland China. Several new and emerging therapies are set to be approved for select subpopulations;…